Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Alnylam Pharmaceuticals, Inc is a biotechnology business based in the US. Alnylam Pharmaceuticals shares (ALNY) are listed on the NASDAQ and all prices are listed in US Dollars. Alnylam Pharmaceuticals employs 1,323 staff and has a trailing 12-month revenue of around USD$345.2 million.
Since the stock market crash in March caused by coronavirus, Alnylam Pharmaceuticals's share price has had significant positive movement.
Its last market close was USD$131.05, which is 0.02% up on its pre-crash value of USD$131.03 and 54.23% up on the lowest point reached during the March crash when the shares fell as low as USD$84.97.
If you had bought USD$1,000 worth of Alnylam Pharmaceuticals shares at the start of February 2020, those shares would have been worth USD$863.80 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,142.76.
|Latest market close||USD$131.05|
|52-week range||USD$84.97 - USD$167.33|
|50-day moving average||USD$135.9794|
|200-day moving average||USD$139.4904|
|Wall St. target price||USD$163.78|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-8.254|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-17)||1.35%|
|1 month (2020-10-27)||3.34%|
|3 months (2020-08-25)||-2.27%|
|6 months (2020-05-23)||N/A|
|1 year (2019-11-25)||16.57%|
|2 years (2018-11-23)||78.69%|
|3 years (2017-11-24)||-1.35%|
|5 years (2015-11-25)||24.51%|
|Revenue TTM||USD$345.2 million|
|Gross profit TTM||USD$194.7 million|
|Return on assets TTM||-18.95%|
|Return on equity TTM||-53.61%|
|Market capitalisation||USD$16.3 billion|
TTM: trailing 12 months
There are currently 3.3 million Alnylam Pharmaceuticals shares held short by investors – that's known as Alnylam Pharmaceuticals's "short interest". This figure is 9.1% down from 3.6 million last month.
There are a few different ways that this level of interest in shorting Alnylam Pharmaceuticals shares can be evaluated.
Alnylam Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Alnylam Pharmaceuticals shares currently shorted divided by the average quantity of Alnylam Pharmaceuticals shares traded daily (recently around 549621.92242833). Alnylam Pharmaceuticals's SIR currently stands at 5.93. In other words for every 100,000 Alnylam Pharmaceuticals shares traded daily on the market, roughly 5930 shares are currently held short.
However Alnylam Pharmaceuticals's short interest can also be evaluated against the total number of Alnylam Pharmaceuticals shares, or, against the total number of tradable Alnylam Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Alnylam Pharmaceuticals's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Alnylam Pharmaceuticals shares in existence, roughly 30 shares are currently held short) or 0.0388% of the tradable shares (for every 100,000 tradable Alnylam Pharmaceuticals shares, roughly 39 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Alnylam Pharmaceuticals.
Find out more about how you can short Alnylam Pharmaceuticals stock.
We're not expecting Alnylam Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Alnylam Pharmaceuticals's shares have ranged in value from as little as $84.97 up to $167.33. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alnylam Pharmaceuticals's is 1.4892. This would suggest that Alnylam Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP). In addition, the company is developing givosiran for the treatment of patients with AHP; lumasiran for the treatment of primary hyperoxaluria type 1, or PH1; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Ionis Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals, Inc., as well as collaboration with Vir Biotechnology, Inc. to advance RNAi therapeutics for the treatment of coronavirus infection, including COVID-19. It also has a collaboration and license agreement with Dicerna Pharmaceuticals, Inc. to develop and commercialize investigational ribonucleic acid interference therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease, as well as Vir Biotechnology, Inc. to develop and commercialize RNAi therapeutics. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Everything we know about the NewRez IPO, plus information on how to buy in.
Everything we know about the Perella Weinberg IPO, plus information on how to buy in.
Everything we know about the Nanobiotix IPO, plus information on how to buy in.
Everything we know about the Diversey IPO, plus information on how to buy in.
Everything we know about the Certara IPO, plus information on how to buy in.
Everything we know about the Arrival IPO, plus information on how to buy in.
Everything we know about the iSpecimen IPO, plus information on how to buy in.
Everything we know about the IDEX Biometrics ASA IPO, plus information on how to buy in.
Steps to owning and managing MYSZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing MG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.